The therapeutic potential of
vorapaxar in patients with non-ST-segment elevation
acute coronary syndrome undergoing
percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of
vorapaxar compared with placebo among
Thrombin Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted
stent type (
drug-eluting stent [DES] vs bare-
metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8%) underwent PCI during index hospitalization, and 3,060 (40.9%) of those patients received exclusively BMS, whereas 4,015 (53.7%) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of
thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death,
myocardial infarction,
stroke, recurrent
ischemia with
rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death,
myocardial infarction, or
stroke) end points did not differ between
vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for
bleeding in patients taking
vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the
stent-type-by-treatment interaction was the duration of
clopidogrel therapy. In conclusion, among patients with PCI, the effect of
vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of
clopidogrel therapy and displayed trends toward greater ischemic benefit from
vorapaxar and lesser
bleeding risk, compared with patients who received a DES.